Biotech Scorecard Q3 Highlights Upcoming Trial Readouts from Amylyx and Biogen

STAT’s quarterly biotech scorecard lists fifteen events that could move biotech stocks, focusing on trial readouts and other milestones.

Amylyx Pharmaceuticals reported results from its Phase 3 LUCIDITY trial of avexitide, a therapy aimed at treating post‑bariatric hypoglycemia, a rare condition that causes dangerous drops in blood sugar.

Biogen disclosed data from a mid‑stage study of diranersen, an experimental Alzheimer’s drug that targets the tau protein, with detailed results slated for presentation at the Alzheimer’s Association International Conference on July 14.